Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists
Valencia, Sarah M
Larson, Nicholas R
Middaugh, C Russell
Picking, William D
Roden, Richard B
Pinto, Ligia A
Shoemaker, Robert H
Ernst, Robert K
Marshall, Jason D
MetadataShow full item record
AbstractCurrent human papilloma virus (HPV) vaccines provide substantial protection against the most common HPV types responsible for oral and anogenital cancers, but many circulating cancer-causing types remain that lack vaccine coverage. The novel RG1-VLP (virus-like particle) vaccine candidate utilizes the HPV16-L1 subunit as a backbone to display an inserted HPV16-L2 17–36 a.a. “RG1” epitope; the L2 RG1 epitope is conserved across many HPV types and the generation of cross-neutralizing antibodies (Abs) against which has been demonstrated. In an effort to heighten the immunogenicity of the RG1-VLP vaccine, we compared in BALB/c mice adjuvant formulations consisting of novel bacterial enzymatic combinatorial chemistry (BECC)-derived toll-like receptor 4 (TLR4) agonists and the aluminum hydroxide adjuvant Alhydrogel. In the presence of BECC molecules, consistent improvements in the magnitude of Ab responses to both HPV16-L1 and the L2 RG1 epitope were observed compared to Alhydrogel alone. Furthermore, neutralizing titers to HPV16 as well as cross-neutralization of pseudovirion (PsV) types HPV18 and HPV39 were augmented in the presence of BECC agonists as well. Levels of L1 and L2-specific Abs were achieved after two vaccinations with BECC/Alhydrogel adjuvant that were equivalent to or greater than levels achieved with 3 vaccinations with Alhydrogel alone, indicating that the presence of BECC molecules resulted in accelerated immune responses that could allow for a decreased dose schedule for VLP-based HPV vaccines. In addition, dose-sparing studies indicated that adjuvantation with BECC/Alhydrogel allowed for a 75% reduction in antigen dose while still retaining equivalent magnitudes of responses to the full VLP dose with Alhydrogel. These data suggest that adjuvant optimization of HPV VLP-based vaccines can lead to rapid immunity requiring fewer boosts, dose-sparing of VLPs expensive to produce, and the establishment of a longer-lasting humoral immunity.
Rights/TermsCopyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14329
- Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
- Authors: Valencia SM, Zacharia A, Marin A, Matthews RL, Wu CK, Myers B, Sanders C, Difilippantonio S, Kirnbauer R, Roden RB, Pinto LA, Shoemaker RH, Andrianov AK, Marshall JD
- Issue date: 2021 Feb 11
- Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
- Authors: Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R
- Issue date: 2017
- Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
- Authors: Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R
- Issue date: 2013 Dec
- Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
- Authors: Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL
- Issue date: 2016 Jul 15
- RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.
- Authors: Huber B, Wang JW, Roden RBS, Kirnbauer R
- Issue date: 2021 Mar 3